Enzon Pharmaceuticals (OTCMKTS:ENZN) Stock Crosses Above 200 Day Moving Average – Should You Sell?

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN)’s share price crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.06 and traded as high as $0.06. Enzon Pharmaceuticals shares last traded at $0.06, with a volume of 602 shares trading hands.

Enzon Pharmaceuticals Stock Performance

The stock’s 50 day simple moving average is $0.06 and its 200 day simple moving average is $0.06. The firm has a market cap of $4.45 million, a PE ratio of -0.86 and a beta of 0.20.

Enzon Pharmaceuticals (OTCMKTS:ENZN) last posted its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.02) earnings per share for the quarter.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.